Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03594721 · ClinicalTrials.gov registry record · NA
Clinical Trial Evaluation of a Test Serum Post HEV (High Energy Visible) Light Exposure
A NA study, sponsored by Allergan.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT03594721 is a NA study that has completed, run by Allergan. The registered enrollment target is 12 participants.
The verdict
NCT03594721, a NA study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
To evaluate 10 days of pretreatment with a serum (Test Product/Marvel AM) to the lower back, followed by a single exposure of 90J/cm2 HEV (High Energy Visible) light {400-450nm wavelengths} in healthy male or female volunteers.
Interventions
- OTHER Marvel AM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-08-06 |
| Est. Completion | 2018-08-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03594721
The ClinicalTrials.gov registry entry for NCT03594721 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Marvel AM is the first listed.
NCT03594721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03594721 about?
NCT03594721 is a clinical study titled "Clinical Trial Evaluation of a Test Serum Post HEV (High Energy Visible) Light Exposure". To evaluate 10 days of pretreatment with a serum (Test Product/Marvel AM) to the lower back, followed by a single exposure of 90J/cm2 HEV (High Energy Visible) light {400-450nm wavelengths} in healthy male or female volunteers.
What is the current status of trial NCT03594721?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2018-08-06. Estimated completion is 2018-08-30.
What interventions are being tested in trial NCT03594721?
The interventions under investigation include: Marvel AM (OTHER).
Who is sponsoring clinical trial NCT03594721?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.